Peter Johannes Holst
Founder & Chief Scientific Officer Hervolution Therapeutics
Peter Holst is the Chief Scientific Officer, Owner and CEO at Hervolution Therapeutics, with expertise in preclinical virology and oncology. He specializes in technology development and evaluation, driving innovative approaches to advance therapeutic research. Peter has a strong track record in leading complex projects and contributing to translational strategies, supported by numerous publications in his field.
Seminars
Tuesday 5th May 2026
Optimizing Tumour Models to Empower Target Validation for IO Therapies
9:30 am
- Identifying and validating target orthologs in mice to ensure accurate immuneoncology efficacy studies
- Employing syngeneic and xenograft mouse models and organoid systems to study tumour growth and immune response dynamics
- Linking the data from these models to elucidate the mode of action of vaccines and guide translational strategies
